{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2025,12,29]],"date-time":"2025-12-29T17:18:58Z","timestamp":1767028738584,"version":"3.48.0"},"reference-count":45,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2025,12,29]],"date-time":"2025-12-29T00:00:00Z","timestamp":1766966400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"},{"start":{"date-parts":[[2025,12,29]],"date-time":"2025-12-29T00:00:00Z","timestamp":1766966400000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"}],"funder":[{"name":"National Institute of Aging","award":["R01AG069900"],"award-info":[{"award-number":["R01AG069900"]}]},{"name":"National Institute of Aging","award":["R01AG069900"],"award-info":[{"award-number":["R01AG069900"]}]},{"name":"National Institute of Aging","award":["R01AG069900"],"award-info":[{"award-number":["R01AG069900"]}]},{"DOI":"10.13039\/100000051","name":"National Human Genome Research Institute","doi-asserted-by":"publisher","award":["U54HG012510"],"award-info":[{"award-number":["U54HG012510"]}],"id":[{"id":"10.13039\/100000051","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100000025","name":"National Institute of Mental Health","doi-asserted-by":"publisher","award":["R01MH137646"],"award-info":[{"award-number":["R01MH137646"]}],"id":[{"id":"10.13039\/100000025","id-type":"DOI","asserted-by":"publisher"}]},{"name":"J & J contract","award":["C2021013133"],"award-info":[{"award-number":["C2021013133"]}]}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Alz Res Therapy"],"abstract":"<jats:title>Abstract<\/jats:title>\n                  <jats:sec>\n                    <jats:title>Background<\/jats:title>\n                    <jats:p>Several health conditions are known to increase the risk of Alzheimer\u2019s disease (AD). We aim to systematically identify medical conditions that are associated with subsequent development of AD by leveraging the growing resources of electronic health records (EHRs).<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Methods<\/jats:title>\n                    <jats:p>\n                      This retrospective cohort study used de-identified EHRs from two independent databases (MarketScan and VUMC) with 153\u00a0million individuals to identify AD cases and age- and gender-matched controls. By tracking their EHRs over a 10-year window before AD diagnosis and comparing the EHRs between AD cases and controls, we identified medical conditions that occur more likely in those who later develop AD. We further assessed the genetic underpinnings of these conditions in relation to AD genetics using data from two large-scale biobanks (BioVU and UK Biobank, total\n                      <jats:italic>N<\/jats:italic>\n                      \u2009=\u2009450,000).\n                    <\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Results<\/jats:title>\n                    <jats:p>We identified 43,508 AD cases and 419,455 matched controls in MarketScan, and 1,320 AD cases and 12,720 matched controls in VUMC. We detected 406 and 102 medical phenotypes that are significantly enriched among the future AD cases in MarketScan and VUMC databases, respectively. In both EHR databases, mental disorders and neurological disorders emerged as the top two most enriched clinical categories. More than 70 medical phenotypes are replicated in both EHR databases, which are dominated by mental disorders (e.g., depression), neurological disorders (e.g., sleep orders), circulatory system disorders (e.g. cerebral atherosclerosis) and endocrine\/metabolic disorders (e.g., type 2 diabetes). We identified 19 phenotypes that are either associated with individual risk variants of AD or a polygenic risk score of AD.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Conclusions<\/jats:title>\n                    <jats:p>In this study, analysis of longitudinal EHRs from independent large-scale databases enables robust identification of health conditions associated with subsequent development of AD, highlighting potential opportunities of therapeutics and interventions to reduce AD risk.<\/jats:p>\n                  <\/jats:sec>","DOI":"10.1186\/s13195-025-01914-4","type":"journal-article","created":{"date-parts":[[2025,12,29]],"date-time":"2025-12-29T17:16:55Z","timestamp":1767028615000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":0,"title":["Longitudinal analysis of electronic health records reveals medical conditions associated with subsequent Alzheimer\u2019s disease development"],"prefix":"10.1186","volume":"17","author":[{"given":"Xue","family":"Zhong","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Gengjie","family":"Jia","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Zhijun","family":"Yin","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Rui","family":"Chen","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Kerou","family":"Cheng","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Andrey","family":"Rzhetsky","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Bingshan","family":"Li","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Nancy J.","family":"Cox","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"297","published-online":{"date-parts":[[2025,12,29]]},"reference":[{"key":"1914_CR1","doi-asserted-by":"publisher","DOI":"10.1136\/bmj.b158","volume":"338","author":"A Burns","year":"2009","unstructured":"Burns A, Iliffe S. Alzheimer\u2019s disease. BMJ. 2009;338:b158. https:\/\/doi.org\/10.1136\/bmj.b158.","journal-title":"BMJ"},{"key":"1914_CR2","doi-asserted-by":"publisher","first-page":"50","DOI":"10.1038\/nature19323","volume":"537","author":"J Sevigny","year":"2016","unstructured":"Sevigny J, et al. The antibody aducanumab reduces Abeta plaques in alzheimer\u2019s disease. Nature. 2016;537:50\u20136. https:\/\/doi.org\/10.1038\/nature19323.","journal-title":"Nature"},{"key":"1914_CR3","doi-asserted-by":"publisher","first-page":"512","DOI":"10.1001\/jama.2023.13239","volume":"330","author":"JR Sims","year":"2023","unstructured":"Sims JR, et al. Donanemab in early symptomatic Alzheimer disease: the TRAILBLAZER-ALZ 2 randomized clinical trial. JAMA. 2023;330:512\u201327. https:\/\/doi.org\/10.1001\/jama.2023.13239.","journal-title":"JAMA"},{"key":"1914_CR4","doi-asserted-by":"publisher","first-page":"9","DOI":"10.1056\/NEJMoa2212948","volume":"388","author":"CH van Dyck","year":"2023","unstructured":"van Dyck CH, et al. Lecanemab in early Alzheimer\u2019s disease. N Engl J Med. 2023;388:9\u201321. https:\/\/doi.org\/10.1056\/NEJMoa2212948.","journal-title":"N Engl J Med"},{"key":"1914_CR5","doi-asserted-by":"publisher","first-page":"1447","DOI":"10.1136\/bmj.322.7300.1447","volume":"322","author":"M Kivipelto","year":"2001","unstructured":"Kivipelto M. Midlife vascular risk factors and Alzheimer\u2019s disease in later life: longitudinal, population based study. BMJ. 2001;322:1447\u201351. https:\/\/doi.org\/10.1136\/bmj.322.7300.1447.","journal-title":"BMJ"},{"key":"1914_CR6","doi-asserted-by":"publisher","first-page":"735","DOI":"10.1016\/S1474-4422(06)70537-3","volume":"5","author":"M Kivipelto","year":"2006","unstructured":"Kivipelto M, et al. Risk score for the prediction of dementia risk in 20 years among middle aged people: a longitudinal, population-based study. Lancet Neurol. 2006;5:735\u201341. https:\/\/doi.org\/10.1016\/S1474-4422(06)70537-3.","journal-title":"Lancet Neurol"},{"key":"1914_CR7","doi-asserted-by":"publisher","first-page":"229","DOI":"10.1002\/alz.12006","volume":"16","author":"J Alber","year":"2020","unstructured":"Alber J, et al. Developing retinal biomarkers for the earliest stages of Alzheimer\u2019s disease: what we know, what we don\u2019t, and how to move forward. Alzheimers Dement. 2020;16:229\u201343. https:\/\/doi.org\/10.1002\/alz.12006.","journal-title":"Alzheimers Dement"},{"key":"1914_CR8","doi-asserted-by":"publisher","first-page":"165","DOI":"10.1159\/000047976","volume":"47","author":"AU Bayer","year":"2002","unstructured":"Bayer AU, Ferrari F, Erb C. High occurrence rate of glaucoma among patients with Alzheimer\u2019s disease. Eur Neurol. 2002;47:165\u20138. https:\/\/doi.org\/10.1159\/000047976.","journal-title":"Eur Neurol"},{"key":"1914_CR9","doi-asserted-by":"publisher","first-page":"753","DOI":"10.1001\/archneur.60.5.753","volume":"60","author":"RC Green","year":"2003","unstructured":"Green RC, et al. Depression as a risk factor for Alzheimer disease: the MIRAGE study. Arch Neurol. 2003;60:753\u20139. https:\/\/doi.org\/10.1001\/archneur.60.5.753.","journal-title":"Arch Neurol"},{"key":"1914_CR10","doi-asserted-by":"publisher","DOI":"10.1371\/journal.pmed.1003016","volume":"17","author":"S Holmquist","year":"2020","unstructured":"Holmquist S, Nordstrom A, Nordstrom P. The association of depression with subsequent dementia diagnosis: a Swedish nationwide cohort study from 1964 to 2016. PLoS Med. 2020;17:e1003016. https:\/\/doi.org\/10.1371\/journal.pmed.1003016.","journal-title":"PLoS Med"},{"key":"1914_CR11","doi-asserted-by":"publisher","first-page":"25","DOI":"10.1515\/fhep-2014-0013","volume":"18","author":"J Zissimopoulos","year":"2014","unstructured":"Zissimopoulos J, Crimmins E, St Clair P. The value of delaying alzheimer\u2019s disease onset. Forum Health Econ Policy. 2014;18:25\u201339. https:\/\/doi.org\/10.1515\/fhep-2014-0013.","journal-title":"Forum Health Econ Policy"},{"key":"1914_CR12","doi-asserted-by":"publisher","first-page":"509","DOI":"10.2147\/CLEP.S206770","volume":"11","author":"A Ponjoan","year":"2019","unstructured":"Ponjoan A, et al. How well can electronic health records from primary care identify Alzheimer\u2019s disease cases? Clin Epidemiol. 2019;11:509\u201318. https:\/\/doi.org\/10.2147\/CLEP.S206770.","journal-title":"Clin Epidemiol"},{"key":"1914_CR13","doi-asserted-by":"publisher","DOI":"10.1371\/journal.pone.0175508","volume":"12","author":"WQ Wei","year":"2017","unstructured":"Wei WQ, et al. Evaluating phecodes, clinical classification software, and ICD-9-CM codes for phenome-wide association studies in the electronic health record. PLoS One. 2017;12:e0175508. https:\/\/doi.org\/10.1371\/journal.pone.0175508.","journal-title":"PLoS One"},{"key":"1914_CR14","doi-asserted-by":"publisher","first-page":"1038","DOI":"10.1016\/j.jalz.2018.02.016","volume":"14","author":"T Wilkinson","year":"2018","unstructured":"Wilkinson T, et al. Identifying dementia cases with routinely collected health data: a systematic review. Alzheimers Dement. 2018;14:1038\u201351. https:\/\/doi.org\/10.1016\/j.jalz.2018.02.016.","journal-title":"Alzheimers Dement"},{"key":"1914_CR15","doi-asserted-by":"publisher","first-page":"1205","DOI":"10.1093\/bioinformatics\/btq126","volume":"26","author":"JC Denny","year":"2010","unstructured":"Denny JC, et al. PheWAS: demonstrating the feasibility of a phenome-wide scan to discover gene-disease associations. Bioinformatics. 2010;26:1205\u201310. https:\/\/doi.org\/10.1093\/bioinformatics\/btq126.","journal-title":"Bioinformatics"},{"issue":"4","key":"1914_CR16","doi-asserted-by":"publisher","first-page":"412","DOI":"10.1038\/s41588-022-01024-z","volume":"54","author":"C Bellenguez","year":"2022","unstructured":"Bellenguez C, et al. New insights into the genetic etiology of Alzheimer\u2019s disease and related dementias. Nat Genet. 2022;54(4):412\u201336. https:\/\/doi.org\/10.1038\/s41588-022-01024-z.","journal-title":"Nat Genet"},{"key":"1914_CR17","doi-asserted-by":"publisher","DOI":"10.1038\/s41467-019-13455-0","volume":"10","author":"G Jia","year":"2019","unstructured":"Jia G, et al. Estimating heritability and genetic correlations from large health datasets in the absence of genetic data. Nat Commun. 2019;10:5508. https:\/\/doi.org\/10.1038\/s41467-019-13455-0.","journal-title":"Nat Commun"},{"key":"1914_CR18","unstructured":"Putting Research Data into Your Hands with the MarketScan Databases. 2016. Available at: http:\/\/truvenhealth.com\/markets\/life-sciences\/products\/data-tools\/marketscan-databases[Accessed 2020 Feb 6]."},{"key":"1914_CR19","doi-asserted-by":"publisher","first-page":"362","DOI":"10.1038\/clpt.2008.89","volume":"84","author":"DM Roden","year":"2008","unstructured":"Roden DM, et al. Development of a large-scale de-identified DNA biobank to enable personalized medicine. Clin Pharmacol Ther. 2008;84:362\u20139. https:\/\/doi.org\/10.1038\/clpt.2008.89.","journal-title":"Clin Pharmacol Ther"},{"key":"1914_CR20","doi-asserted-by":"publisher","first-page":"1345","DOI":"10.1038\/ng.2795","volume":"45","author":"R Do","year":"2013","unstructured":"Do R, et al. Common variants associated with plasma triglycerides and risk for coronary artery disease. Nat Genet. 2013;45:1345\u201352. https:\/\/doi.org\/10.1038\/ng.2795.","journal-title":"Nat Genet"},{"key":"1914_CR21","doi-asserted-by":"publisher","first-page":"1279","DOI":"10.1038\/ng.3643","volume":"48","author":"S McCarthy","year":"2016","unstructured":"McCarthy S, et al. A reference panel of 64,976 haplotypes for genotype imputation. Nat Genet. 2016;48:1279\u201383. https:\/\/doi.org\/10.1038\/ng.3643.","journal-title":"Nat Genet"},{"key":"1914_CR22","doi-asserted-by":"publisher","DOI":"10.1371\/journal.pgen.1000529","volume":"5","author":"BN Howie","year":"2009","unstructured":"Howie BN, Donnelly P, Marchini J. A flexible and accurate genotype imputation method for the next generation of genome-wide association studies. PLoS Genet. 2009;5:e1000529. https:\/\/doi.org\/10.1371\/journal.pgen.1000529.","journal-title":"PLoS Genet"},{"key":"1914_CR23","doi-asserted-by":"publisher","DOI":"10.1136\/bmjopen-2015-009161","volume":"6","author":"J Hewitt","year":"2016","unstructured":"Hewitt J, Walters M, Padmanabhan S, Dawson J. Cohort profile of the UK biobank: diagnosis and characteristics of cerebrovascular disease. BMJ Open. 2016;6:e009161. https:\/\/doi.org\/10.1136\/bmjopen-2015-009161.","journal-title":"BMJ Open"},{"key":"1914_CR24","doi-asserted-by":"publisher","first-page":"2375","DOI":"10.1093\/bioinformatics\/btu197","volume":"30","author":"RJ Carroll","year":"2014","unstructured":"Carroll RJ, Bastarache L, Denny JC. R phewas: data analysis and plotting tools for phenome-wide association studies in the R environment. Bioinformatics. 2014;30:2375\u20136. https:\/\/doi.org\/10.1093\/bioinformatics\/btu197.","journal-title":"Bioinformatics"},{"key":"1914_CR25","doi-asserted-by":"publisher","first-page":"290","DOI":"10.1038\/s41586-021-03205-y","volume":"590","author":"D Taliun","year":"2021","unstructured":"Taliun D, et al. Sequencing of 53,831 diverse genomes from the NHLBI topmed program. Nature. 2021;590:290\u20139. https:\/\/doi.org\/10.1038\/s41586-021-03205-y.","journal-title":"Nature"},{"key":"1914_CR26","doi-asserted-by":"publisher","first-page":"1335","DOI":"10.1038\/s41588-018-0184-y","volume":"50","author":"W Zhou","year":"2018","unstructured":"Zhou W, et al. Efficiently controlling for case-control imbalance and sample relatedness in large-scale genetic association studies. Nat Genet. 2018;50:1335\u201341. https:\/\/doi.org\/10.1038\/s41588-018-0184-y.","journal-title":"Nat Genet"},{"key":"1914_CR27","doi-asserted-by":"publisher","first-page":"365","DOI":"10.1007\/s00401-013-1157-y","volume":"126","author":"GG Kovacs","year":"2013","unstructured":"Kovacs GG, et al. Non-Alzheimer neurodegenerative pathologies and their combinations are more frequent than commonly believed in the elderly brain: a community-based autopsy series. Acta Neuropathol. 2013;126:365\u201384. https:\/\/doi.org\/10.1007\/s00401-013-1157-y.","journal-title":"Acta Neuropathol"},{"key":"1914_CR28","doi-asserted-by":"publisher","DOI":"10.1186\/s13195-014-0082-1","volume":"6","author":"J Rahimi","year":"2014","unstructured":"Rahimi J, Kovacs GG. Prevalence of mixed pathologies in the aging brain. Alzheimers Res Ther. 2014;6:82. https:\/\/doi.org\/10.1186\/s13195-014-0082-1.","journal-title":"Alzheimers Res Ther"},{"key":"1914_CR29","doi-asserted-by":"publisher","first-page":"953","DOI":"10.1093\/brain\/awaa438","volume":"144","author":"JL Robinson","year":"2021","unstructured":"Robinson JL, et al. The development and convergence of co-pathologies in Alzheimer\u2019s disease. Brain. 2021;144:953\u201362. https:\/\/doi.org\/10.1093\/brain\/awaa438.","journal-title":"Brain"},{"key":"1914_CR30","doi-asserted-by":"publisher","first-page":"2557","DOI":"10.1093\/brain\/awad059","volume":"146","author":"JL Robinson","year":"2023","unstructured":"Robinson JL, et al. Pathological combinations in neurodegenerative disease are heterogeneous and disease-associated. Brain. 2023;146:2557\u201369. https:\/\/doi.org\/10.1093\/brain\/awad059.","journal-title":"Brain"},{"key":"1914_CR31","doi-asserted-by":"publisher","DOI":"10.1002\/trc2.12465","volume":"10","author":"J Cummings","year":"2024","unstructured":"Cummings J. Alzheimer\u2019s disease drug development pipeline: 2024. Alzheimer\u2019s & Dementia: Translational Research & Clinical Interventions. 2024;10:e12465. https:\/\/doi.org\/10.1002\/trc2.12465.","journal-title":"Alzheimer's & Dementia: Translational Research & Clinical Interventions"},{"key":"1914_CR32","doi-asserted-by":"publisher","unstructured":"Brainstorm C, et al. Analysis of shared heritability in common disorders of the brain. Science. 2018;360. https:\/\/doi.org\/10.1126\/science.aap8757.","DOI":"10.1126\/science.aap8757"},{"key":"1914_CR33","doi-asserted-by":"publisher","first-page":"404","DOI":"10.1038\/s41588-018-0311-9","volume":"51","author":"IE Jansen","year":"2019","unstructured":"Jansen IE, et al. Genome-wide meta-analysis identifies new loci and functional pathways influencing Alzheimer\u2019s disease risk. Nat Genet. 2019;51:404\u201313. https:\/\/doi.org\/10.1038\/s41588-018-0311-9.","journal-title":"Nat Genet"},{"key":"1914_CR34","doi-asserted-by":"publisher","first-page":"25","DOI":"10.1016\/j.biopsych.2021.11.025","volume":"92","author":"NV Harerimana","year":"2022","unstructured":"Harerimana NV, et al. Genetic evidence supporting a causal role of depression in Alzheimer\u2019s disease. Biol Psychiatry. 2022;92:25\u201333. https:\/\/doi.org\/10.1016\/j.biopsych.2021.11.025.","journal-title":"Biol Psychiatry"},{"key":"1914_CR35","doi-asserted-by":"publisher","DOI":"10.1038\/s41467-022-31873-5","volume":"13","author":"TS Wingo","year":"2022","unstructured":"Wingo TS, et al. Shared mechanisms across the major psychiatric and neurodegenerative diseases. Nat Commun. 2022;13:4314. https:\/\/doi.org\/10.1038\/s41467-022-31873-5.","journal-title":"Nat Commun"},{"key":"1914_CR36","doi-asserted-by":"crossref","unstructured":"Ajneesh Kumar NRR, Cuccaro ML, Gary Beecham, Edward D, Huey CR. Genetic correlation analysis identifies genetic loci shared between Alzheimer\u2019s disease and primary psychiatric disorders. (https:\/\/alz.confex.com\/alz\/2024\/meetingapp.cgi\/Paper\/93421, Alzheimer\u2019s Association International Conference2024).","DOI":"10.1002\/alz.093421"},{"key":"1914_CR37","doi-asserted-by":"publisher","DOI":"10.1038\/s41467-017-02395-2","volume":"9","author":"P Aramillo Irizar","year":"2018","unstructured":"Aramillo Irizar P, et al. Transcriptomic alterations during ageing reflect the shift from cancer to degenerative diseases in the elderly. Nat Commun. 2018;9:327. https:\/\/doi.org\/10.1038\/s41467-017-02395-2.","journal-title":"Nat Commun"},{"key":"1914_CR38","doi-asserted-by":"publisher","first-page":"547","DOI":"10.1007\/s10522-014-9523-2","volume":"15","author":"JA Driver","year":"2014","unstructured":"Driver JA. Inverse association between cancer and neurodegenerative disease: review of the epidemiologic and biological evidence. Biogerontology. 2014;15:547\u201357. https:\/\/doi.org\/10.1007\/s10522-014-9523-2.","journal-title":"Biogerontology"},{"key":"1914_CR39","doi-asserted-by":"publisher","DOI":"10.1136\/bmj.e1442","volume":"344","author":"JA Driver","year":"2012","unstructured":"Driver JA, et al. Inverse association between cancer and Alzheimer\u2019s disease: results from the Framingham Heart Study. BMJ. 2012;344:e1442. https:\/\/doi.org\/10.1136\/bmj.e1442.","journal-title":"BMJ"},{"key":"1914_CR40","doi-asserted-by":"publisher","DOI":"10.1001\/jamanetworkopen.2019.6160","volume":"2","author":"M Ospina-Romero","year":"2019","unstructured":"Ospina-Romero M, et al. Rate of memory change before and after cancer diagnosis. JAMA Netw Open. 2019;2:e196160. https:\/\/doi.org\/10.1001\/jamanetworkopen.2019.6160.","journal-title":"JAMA Netw Open"},{"key":"1914_CR41","doi-asserted-by":"publisher","first-page":"106","DOI":"10.1212\/WNL.0b013e3181c91873","volume":"74","author":"CM Roe","year":"2010","unstructured":"Roe CM, et al. Cancer linked to Alzheimer disease but not vascular dementia. Neurology. 2010;74:106\u201312. https:\/\/doi.org\/10.1212\/WNL.0b013e3181c91873.","journal-title":"Neurology"},{"key":"1914_CR42","doi-asserted-by":"publisher","DOI":"10.1098\/rsif.2014.0919","volume":"12","author":"LA Demetrius","year":"2015","unstructured":"Demetrius LA, Driver JA. Preventing Alzheimer\u2019s disease by means of natural selection. J R Soc Interface. 2015;12:20140919. https:\/\/doi.org\/10.1098\/rsif.2014.0919.","journal-title":"J R Soc Interface"},{"key":"1914_CR43","doi-asserted-by":"publisher","DOI":"10.1001\/jamanetworkopen.2019.6167","volume":"2","author":"OI Okereke","year":"2019","unstructured":"Okereke OI, Meadows ME. More evidence of an inverse association between cancer and Alzheimer disease. JAMA Netw Open. 2019;2:e196167. https:\/\/doi.org\/10.1001\/jamanetworkopen.2019.6167.","journal-title":"JAMA Netw Open"},{"issue":"11","key":"1914_CR44","doi-asserted-by":"publisher","first-page":"1141","DOI":"10.1002\/pon.3196","volume":"21","author":"TA Ahles","year":"2012","unstructured":"Ahles TA. Brain vulnerability to chemotherapy toxicities. Psychooncology. 2012;21(11):1141\u20138. https:\/\/doi.org\/10.1002\/pon.3196.","journal-title":"Psychooncology"},{"key":"1914_CR45","doi-asserted-by":"publisher","first-page":"e20","DOI":"10.1093\/jamia\/ocv130","volume":"23","author":"WQ Wei","year":"2016","unstructured":"Wei WQ, et al. Combining billing codes, clinical notes, and medications from electronic health records provides superior phenotyping performance. J Am Med Inf Assoc. 2016;23:e20\u201327. https:\/\/doi.org\/10.1093\/jamia\/ocv130.","journal-title":"J Am Med Inf Assoc"}],"container-title":["Alzheimer's Research &amp; Therapy"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s13195-025-01914-4.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1186\/s13195-025-01914-4","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s13195-025-01914-4.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,12,29]],"date-time":"2025-12-29T17:16:56Z","timestamp":1767028616000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1186\/s13195-025-01914-4"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,12,29]]},"references-count":45,"journal-issue":{"issue":"1","published-online":{"date-parts":[[2025,12]]}},"alternative-id":["1914"],"URL":"https:\/\/doi.org\/10.1186\/s13195-025-01914-4","relation":{},"ISSN":["1758-9193"],"issn-type":[{"value":"1758-9193","type":"electronic"}],"subject":[],"published":{"date-parts":[[2025,12,29]]},"assertion":[{"value":"24 February 2025","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"10 November 2025","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"29 December 2025","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"All human subjects used in this study have provided informed consent by the previous studies. The de-identified mirror of the VUMC EHR system in ongoing research projects is classified as non-human subject research by the VUMC Institutional Review Board (IRB).","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethics approval and consent to participate"}},{"value":"All authors approved the final version of the manuscript and consent for publication.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Consent for publication"}},{"value":"The authors declare no competing interests.","order":4,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}}],"article-number":"263"}}